The Hand Eczema (HE) Treatment market is valued at USD 61.82 Million in 2025. As per FMI's analysis, the Hand Eczema Treatment sector will grow at a CAGR of 8% and reach USD 133.46 Million by 2035.
In 2024, the industry witnessed a steady increase in demand driven by heightened awareness around skin-related conditions, particularly in developed regions. Increased spending on healthcare and skincare solutions, coupled with a growing understanding of the condition, fueled the growth.
Pharmaceutical companies introduced new treatments and topical solutions, further enhancing the availability of effective treatments. Notably, regulatory bodies streamlined the approval processes, making it easier for companies to bring new products to industry. Moreover, digital platforms played a pivotal role in educating patients, which contributed to a larger patient base seeking treatment.
Looking ahead to 2025 and beyond, the industry is expected to continue on its growth trajectory. With advancements in research and development, more targeted therapies will likely emerge, offering improved efficacy. Furthermore, increasing focus on natural and holistic treatments could broaden the industry landscape.
As the global population ages, the prevalence of hand eczema may also rise, further driving demand for treatments. By 2035, the industry will see significant growth, driven by continued innovations and greater patient awareness.
Hand Eczema Market Statistics
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 61.82 million |
| Industry Value (2035F) | USD 133.46 million |
| CAGR (2025 to 2035) | 8% |
The Hand Eczema Treatment industry is on an upward trajectory, fueled by rising awareness, increased healthcare spending, and advancements in treatment options. Key drivers include growing demand for more effective, targeted therapies and the rising prevalence of skin conditions. Pharmaceutical companies, especially those focusing on topical treatments and natural solutions, are positioned to benefit, while those unable to innovate may struggle to maintain industry share.
Explore FMI!
Book a free demo
Executives in the Hand Eczema Treatment industry should focus on investing in research and development to create more effective, targeted therapies that cater to the growing demand for personalized skin care solutions. Integrating digital health technologies and AI-driven diagnostics will become key differentiators in improving treatment outcomes and patient adherence.
Additionally, the shift toward natural and eco-friendly ingredients in treatments will align with rising consumer demand for sustainable, less harmful products, positioning companies to thrive under increasing regulatory scrutiny.
Strategic partnerships with healthcare providers and digital health platforms will be essential to expand reach and improve patient access to treatments. Companies should target high-growth regions like Asia-Pacific, where rising awareness of dermatological conditions is creating a larger patient base, while also tapping into mature markets in North America and Europe, where demand for innovative treatments is on the rise.
The industry faces several challenges, with stringent regulations on pharmaceutical ingredients posing a high-impact risk, requiring proactive R&D investments in eco-friendly and compliant solutions. The ongoing economic fluctuations that affect healthcare budgets present a medium-risk challenge, urging careful financial planning. Additionally, supply chain disruptions could delay product availability, making it essential to develop flexible sourcing strategies to maintain a steady supply of treatments.
| Countries | Regulatory Impact |
|---|---|
| USA | In the United States, the FDA plays a key role in regulating pharmaceutical treatments for hand eczema. Companies must meet stringent FDA approval processes for drugs and topical treatments. Additionally, the FDA ensures compliance with Good Manufacturing Practices (GMP). Companies must also be aware of the Drug Approval Process and adhere to the Drug Enforcement Administration (DEA) regulations for controlled substances as per FDA. |
| UK | In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) governs the approval of dermatological treatments. Regulations require strict clinical trials and product safety assessments for approval. Additionally, the Cosmetic Products Regulation (CPR) outlines rules for non-drug treatments like moisturizers. Compliance with these regulations is necessary for industry entry as per MHRA. |
| France | The French National Agency for the Safety of Medicines and Health Products (ANSM) oversees the approval and regulation of skin treatments. Both drug and cosmetic products must comply with EU regulations, with a focus on ensuring the safety of ingredients, particularly in the case of natural treatments as per ANS M. |
| Germany | In Germany, the Federal Institute for Drugs and Medical Devices ( BfArM ) regulates pharmaceutical products, while cosmetic treatments are overseen by the Federal Office of Consumer Protection. The industry is heavily influenced by EU-wide regulations, including REACH, for the safety of chemicals used in products as per BfArM. |
| Italy | Italy follows EU regulations, with the Italian Medicines Agency (AIFA) regulating medicinal treatments for skin diseases. Companies must also adhere to the EU Cosmetics Regulation for non-medical treatments. Certification for product safety and clinical testing is crucial for industry approval as per AIFA. |
| South Korea | In South Korea, the Ministry of Food and Drug Safety (MFDS) regulates the approval of hand eczema treatments. The country has stringent rules for the approval of both over-the-counter and prescription products. South Korea also emphasizes the use of digital health solutions for dermatology, which may require specific certifications as per MFDS. |
| Japan | Japan's Pharmaceuticals and Medical Devices Agency (PMDA) oversees the approval of drugs for treating skin conditions. Companies must adhere to strict regulations for clinical trials, labeling , and product safety. The Japanese industry also demands adherence to environmental and sustainability regulations in the formulation of treatments. (Source: PMDA) |
| China | In China, the National Medical Products Administration (NMPA) regulates the approval of skin treatments. Companies must comply with NMPA standards, including the requirements for clinical trials and post- industry surveillance. The use of herbal and natural ingredients is particularly scrutinized under China's health product regulations as per NMPA. |
| Australia-NZ | In Australia, the Therapeutic Goods Administration (TGA) is responsible for regulating hand eczema treatments, ensuring compliance with stringent clinical and safety standards. In New Zealand, the Medsafe authority oversees drug approvals. Both countries require adherence to the Therapeutic Goods Administration Act and New Zealand’s Medicines Act for approval as per TGA, Medsafe |
UV Therapy is the fastest-growing segment in the Hand Eczema Treatment industry, with the highest CAGR of 10%. This treatment, though niche, is gaining traction due to its effectiveness in treating severe cases of hand eczema that do not respond well to conventional treatments. UV therapy involves controlled exposure to ultraviolet light, which helps reduce inflammation and skin irritation.
It is increasingly being preferred for patients with chronic or resistant eczema, contributing to its growth. As awareness of its benefits grows, especially in severe cases, the segment is poised for substantial expansion in the coming years, offering a lucrative opportunity for companies investing in advanced UV-based technologies.
Online Pharmacy is expected to experience significant growth, with a CAGR of 10%, the highest among all end-user channels. This rapid growth is driven by the increasing trend of digital health solutions and the shift toward e-commerce for purchasing medications. Online pharmacies offer convenience, faster delivery, and easier access to a wide range of eczema treatments, particularly for those living in remote areas.
As consumers embrace digital healthcare platforms for their medication needs, online pharmacies are well-positioned to capture a larger share of the Hand Eczema Treatment industry, making it a highly lucrative segment in the years to come.
Sales in the United States are anticipated to grow at a CAGR of 8% from 2025 to 2035. The USA industry remains one of the largest and most lucrative for hand eczema treatments, driven by the high prevalence of the condition and the presence of advanced healthcare infrastructure.
The increasing demand for innovative treatment options, especially in retail and online pharmacies, will further propel industry growth. Regulatory frameworks support new treatment approvals, and with growing awareness of eczema management, this industry continues to be a primary focus for manufacturers of topical corticosteroids, calcineurin inhibitors, and UV therapy solutions.
The industry in the United Kingdomis anticipated to grow at a CAGR of 7.5% from 2025 to 2035. Despite a highly developed healthcare system, the UK’s hand eczema treatment industry is expected to face moderate growth. A key factor driving demand will be an aging population, which often experiences dermatological conditions like eczema.
However, economic pressures and budgetary constraints within the National Health Service (NHS) may limit the industry’s expansion. There is also a growing preference for online pharmacies as an alternative to traditional healthcare channels, which will slightly boost growth in this segment moving forward.
Sales in France are anticipated to grow at a CAGR of 7.8% from 2025 to 2035. The French industry for hand eczema treatment is expected to see steady growth, supported by advancements in dermatological research and a relatively high demand for quality care in major cities.
The healthcare system in France offers robust access to treatment options, and there is a growing trend of patients seeking non-steroid options like calcineurin inhibitors. Retail and hospital pharmacies will continue to dominate, though online pharmacies are projected to experience moderate growth as digital healthcare solutions become more widely accepted.
In Germany sales are anticipated to grow at a CAGR of 7.5% from 2025 to 2035. Germany, with its strong healthcare infrastructure, will experience steady but moderate growth in the hand eczema treatment industry. The country’s aging population and focus on high-quality healthcare are key drivers for industry expansion.
However, regulatory scrutiny over new treatments and the increasing popularity of non-prescription treatments like topical corticosteroids may create challenges. Still, innovations in dermatology, coupled with strong healthcare spending, will keep Germany as a stable and important player in this space. Online pharmacies are expected to see some growth as well.
The industry in Italy is anticipated to grow at a CAGR of 7.6% from 2025 to 2035. Italy's hand eczema treatment industry will experience steady growth driven by the country’s well-established healthcare system and a high level of awareness regarding chronic skin conditions.
However, industry growth will be tempered by economic factors, which may limit the adoption of high-end treatment options like UV therapy. The industry will still see moderate demand for topical corticosteroids and calcineurin inhibitors, especially in retail pharmacies. Additionally, there is potential for growth in online pharmacy sales as consumers increasingly turn to digital platforms for healthcare.
South Korea sales are anticipated to grow at a CAGR of 8.5% from 2025 to 2035. South Korea is expected to see robust industry growth due to its rapidly advancing healthcare system and high demand for effective treatment options.
The country has a strong preference for innovative and technologically advanced therapies, which bodes well for segments like UV therapy and calcineurin inhibitors. Moreover, an increasing number of consumers are shifting toward online pharmacies for convenience, which will further drive growth. The combination of high healthcare spending and a tech-savvy population positions South Korea as a key growth region in the hand eczema treatment industry.
The industry in Japan is anticipated to grow at a CAGR of 7.5% from 2025 to 2035. Japan’s industry for hand eczema treatments is expected to grow at a moderate pace, largely driven by the country’s aging population. As chronic conditions like eczema become more prevalent among the elderly, there will be a greater demand for treatment options.
However, Japan’s mature healthcare system means that the industry is somewhat saturated, and there is little room for explosive growth. Nevertheless, the growing trend of digital healthcare solutions and the need for new, innovative therapies will continue to support steady growth in the industry.
In China sales are anticipated to grow at a CAGR of 9% from 2025 to 2035. China represents one of the fastest-growing regions for hand eczema treatments, driven by its large population and growing healthcare expenditure.
The industry is expanding rapidly due to increasing awareness of eczema and a growing middle class with more disposable income to spend on healthcare. As demand for both conventional and alternative treatments rises, manufacturers are looking to capitalize on this opportunity by offering affordable and effective solutions. The online pharmacy segment is also expected to thrive in China as more consumers seek convenient ways to access treatment.
In Australia and New Zealand sector is anticipated to grow at a CAGR of 8.2% from 2025 to 2035. The industry in these countries will experience steady growth, driven by high healthcare standards, an aging population, and increasing awareness of skin conditions like hand eczema.
Australia, in particular, is witnessing a surge in demand for eczema treatments, and the online pharmacy sector is gaining popularity due to the convenience and accessibility it offers. While traditional pharmacies will remain important, digital health platforms and e-commerce are expected to play an increasing role in shaping industry dynamics in this region.
The hand eczema treatment industry has seen notable advancements in 2024, with several key players focusing on innovative therapies. DermTech launched a new AI-driven diagnostic tool to personalize treatment plans for severe hand eczema cases, enhancing therapeutic outcomes as per IEE Explore. Additionally, the FDA fast-tracked a novel UV therapy device from Philips, designed for at-home use, which could significantly improve patient compliance as per FDA.
Online pharmacies like Hims & Hers also entered the industry, offering telemedicine consultations and direct delivery of prescribed treatments, reflecting the sector's shift toward digital health solutions as per hims. These developments highlight a growing emphasis on precision medicine and accessibility in hand eczema care.
In 2024, Sanofi (15-20% industry share)maintain its leadership in the hand eczema treatment industry with its robust portfolio of topical corticosteroids and innovative biologic therapies. Incyte Corporation (10-15%) is expanding its presence with targeted therapies such as ruxolitinib, gaining traction due to its efficacy in managing moderate to severe eczema. Asana Biosciences (8-12%) is making significant strides with its new formulations, aiming to address unmet needs in chronic hand eczema treatments, particularly for patients seeking non-steroidal options.
Leo Pharma (7-10%) is enhancing its footprint with a range of topical calcineurin inhibitors, capitalizing on the growing preference for steroid-sparing treatments. Regeneron Pharmaceuticals (6-9%) is expanding its industry share with Dupixent, which is gaining popularity as a biologic option for moderate to severe cases of hand eczema. Meda AB (5-8%) is focusing on accessible and cost-effective topical treatments, maintaining a strong presence in retail pharmacies.
AstraZeneca (4-6%) is pursuing new partnerships and clinical trials to diversify its portfolio of eczema treatments, especially in the biologic space. Pfizer (3-5%) continues to strengthen its role with topical therapies and oral medications in both the retail and hospital pharmacy sectors. GlaxoSmithKline plc (2-4%) is focusing on a growing range of treatments for patients with chronic hand eczema, especially through online pharmacy distribution. Anacor Pharmaceuticals (2-3%) is gaining recognition with its novel therapies designed for long-term use, catering to patients with persistent eczema symptoms.
The Hand Eczema Treatment industry is projected to grow at a CAGR of 8% from 2025 to 2035.
Growth is driven by increased awareness, advancements in treatment options, and rising healthcare spending.
Demand will rise due to an aging population, greater patient awareness, and innovations in targeted therapies.
Asia-Pacific, North America, and Europe are expected to see the highest growth due to rising awareness and demand for treatments.
Digital platforms will expand patient education and accessibility, driving treatment adoption and awareness.
the industry is segmented into topical corticosteroids, topical calcineurin inhibitors and UV therapy
the industry is divided into retail pharmacy, hospital pharmacy and online pharmacy
the industry is studied across North America, Latin America, Europe, Asia Pacific, Middle East & Africa
Hand Eczema (HE) Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
